Editas Medicine (EDIT) Cash from Investing Activities (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash from Investing Activities data on file, last reported at $39.6 million in Q3 2025.

• Quarterly Cash from Investing Activities fell 52.88% year-over-year to $39.6 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $169.6 million (down 12.61% YoY) and the FY2024 annual result came in at $162.1 million, up 4445.91% from the prior year.
• Cash from Investing Activities eased to $39.6 million in Q3 2025 per EDIT's latest filing, from $42.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $89.2 million in Q3 2022 and bottomed at -$102.8 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is $23.3 million (2023), against an average of $18.8 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities soared 1637.7%; it then slumped 215.23% in 2023.
• Tracing EDIT's Cash from Investing Activities over 5 years: stood at -$22.8 million in 2021, then slipped by 20.53% to -$27.5 million in 2022, then surged by 328.28% to $62.8 million in 2023, then plunged by 50.74% to $31.0 million in 2024, then grew by 27.83% to $39.6 million in 2025.
• Per Business Quant, the three latest EDIT Cash from Investing Activities figures stand at $39.6 million (Q3 2025), $42.6 million (Q2 2025), and $56.4 million (Q1 2025).

Peer Comparison